Literature DB >> 32419041

Short and mid-term outcomes of multimodal treatment for locally-advanced non-small cell lung cancer in elderly patients.

Stefano Bongiolatti1, Francesca Mazzoni2, Alessandro Gonfiotti1, Giulia Di Pierro2, Alberto Salvicchi3, Sara Borgianni1, Katia Ferrari4, Luca Voltolini1.   

Abstract

OBJECTIVE: Multimodality treatments are effective for locally advanced non-small cell lung cancer (LA-NSCLC) showing benefits in overall (OS) and disease-free survival (DFS), but these options are frequently denied to elderly patients.
METHODS: The objectives of this retrospective study were: to investigate mortality, morbidity and oncological outcomes of pulmonary resection after induction therapy (IT) for NSCLC in elderly patients. We divided the cohort into two: patients < 70 years (group A) and patients ≥70 years (group B). A multivariable logistic regression was built to identify factors associated with morbidity.
RESULTS: 77 patients underwent pulmonary resection after IT, 27 were aged ≥70 years. Type of chemotherapy, surgical procedures, pathological stages were comparable between the two groups, while the preoperative use of chemo-radiation therapy regimen was more frequent in group A (p = 0.027). In-hospital mortality was similar, while the percentage of patients with complications (38% vs 48.1%, p = 0.47) and the complication rate (50% vs 77%, p = 0.01) were higher in group B, but the severity of complications was comparable. The multivariable analysis did not identify any risk factors associated with morbidity. OS at 3 years and DFS at 2 years were not different (61% vs 48.5%, p = 0.64; 61.7% vs 44%, p = 0.393).
CONCLUSIONS: Lung resection for LA-NSCLC after IT can be performed safely in selected elderly patients with favourable postoperative and mid-term oncological results.

Entities:  

Keywords:  Elderly; Locally-advanced NSCLC; NSCLC multimodal treatment; Neoadjuvant therapy; Survival

Mesh:

Year:  2020        PMID: 32419041     DOI: 10.1007/s11748-020-01384-5

Source DB:  PubMed          Journal:  Gen Thorac Cardiovasc Surg        ISSN: 1863-6705


  2 in total

1.  Efficacy and Safety of Anlotinib Monotherapy as Third-Line Therapy for Elderly Patients with Non-Small Cell Lung Cancer: A Real-World Exploratory Study.

Authors:  Hong-Tao Jiang; Wei Li; Biao Zhang; Qiang Gong; Hai-Ling Qie
Journal:  Int J Gen Med       Date:  2021-11-02

2.  Impact of Systematic Holistic Nursing Combined with Narrative Nursing Intervention for Patients with Advanced Gastric Cancer on Complications and Negative Emotions.

Authors:  Hui Lu; Lingyun Zhu; Chunxiao Tan
Journal:  Evid Based Complement Alternat Med       Date:  2022-07-15       Impact factor: 2.650

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.